AngioDynamics Reports Strong Q3 Sales, Improved YTD Loss, and Favorable Patent Ruling
ANGO sits 25% above its 52-week low of $8.36.
Summary
AngioDynamics reported an 8.9% increase in Q3 net sales, driven by 19% growth in its Med Tech segment, and a reduced net loss for the nine-month period, alongside a favorable patent litigation ruling.
Key Events · Earnings and Guidance · ANGO
-
Q3 FY26 Net Sales Growth
Net sales increased by 8.9% to $78.4 million for the three months ended February 28, 2026, compared to $72.0 million in the prior year period.
-
Improved Nine-Month Net Loss
The company reported a net loss of $25.3 million for the nine months ended February 28, 2026, an improvement from a net loss of $27.9 million in the same period last year.
-
Strong Med Tech Segment Performance
The Med Tech segment, including Auryon, thrombus management, and NanoKnife, saw net sales grow by 19.0% in Q3 and 19.1% for the nine-month period.
-
Favorable Patent Litigation Outcome
The Federal Circuit affirmed the District Court's finding of patent invalidity in the C.R. Bard case on December 15, 2025, in favor of AngioDynamics, meaning no additional contingent payments are due beyond the minimum annual payments.
Analysis · ANGO · Industrial Applications And Services
AngioDynamics' latest 10-Q filing details a mixed but overall positive financial performance, highlighted by robust growth in its Med Tech segment and a favorable resolution in a significant patent litigation. While the net loss for the third quarter increased, the nine-month year-to-date net loss significantly improved, and operating cash flow showed a strong positive trend. The Federal Circuit's affirmation of patent invalidity in the C.R. Bard case is a material positive development, reducing future contingent payment obligations. Investors should note the continued strategic focus on Med Tech and the improved operational efficiency, alongside the positive legal outcome.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANGO was trading at $10.47 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $431.5M. The 52-week trading range was $8.36 to $13.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.